Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.77 |
| ▸ | CTSC | P53634 | 10/20 | 0.77 |
| ▸ | PLK4 | O00444 | 1/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.77 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | FLT3 | P36888 | 1/20 | 0.77 |
| ▸ | BLK | P51451 | 1/20 | 0.77 |
| ▸ | BMX | P51813 | 1/20 | 0.77 |
| ▸ | JAK3 | P52333 | 1/20 | 0.77 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.77 |
| ▸ | BTK | Q06187 | 1/20 | 0.77 |
| ▸ | ITK | Q08881 | 1/20 | 0.77 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.77 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 0.77 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.77 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.77 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.77 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371094 | 0.93 | EGFR (0.72) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL2047564 | 0.91 | EGFR (0.63) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL18018943 | 0.90 | EGFR (0.69) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL10127995 | 0.87 | EGFR (0.80) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL29733655 | 0.87 | EGFR (1.00) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL29354966 | 0.87 | EGFR (1.00) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL93699 | 0.87 | EGFR (1.00) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL12371098 | 0.86 | CTSC (0.74) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL1706773 | 0.85 | EGFR (0.97) | EGFRCTSCPLK4GAKNUAK1 | |
| SCHEMBL2040938 | 0.85 | EGFR (0.74) | EGFRCTSCPLK4GAKNUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | EGFR 2819/4885CTSC 2039/4885PLK4 1770/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | EGFR 2819/4885CTSC 2039/4885PLK4 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.